drugset / Trial / NCT03521232

A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis

NCT03521232

Phase 1/2 Terminated 27 enrolled Entero Therapeutics
Non-randomizedParallel-groupOpen-labelOther

Summary

This will be a phase I/IIa, open-label, three-stage, single center study aimed at investigating the safety, the efficacy (clinical and endoscopic effects) and the pharmacokinetics of Niclosamide enema 150 mg/60 ml and 450 mg/60 ml in subjects with mild-to-moderate UP and UPS, defined as a Modified Mayo Score (MMS) ≥ 4 and \< 8, with a stool frequency subscore (SFS) ≥ 1, a rectal bleeding sub-score (RBS) = 1 or 2, and an endoscopic subscore (mucosal appearance) = 1 or 2. At the endoscopic sub-score any degree of friability will be classified as having a sub-scale score of 2.

Timeline

Start
2018-05-15
Primary completion
2022-09-19
Completion
2022-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Niclosamide Unknown 150 mg
Subject Niclosamide Unknown 450 mg